Recent Updates
Recently added Catalysts
TVTX Positive Sentiment

Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental Glomerulosclerosis

Wednesday, September 23, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Travere Therapeutics has received a Notice of Allowance from the USPTO for its patent application concerning methods of using FILSPARI (sparsentan) to treat focal segmental glomerulosclerosis (FSGS). This patent, once issued, will provide U.S. patent protection for specific applications of the drug, potentially strengthening the company's market position in the treatment of kidney diseases.

Market Sentiment Analysis

POSITIVE FACTORS

  • Notice of Allowance indicates progress in patent application.
  • Patent will provide U.S. coverage for FILSPARI in treating FSGS.
  • Potential for enhanced market position for Travere Therapeutics.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+68%
120-day peak, hindsight
Typical move
8.6%
average across 10 past catalysts
Lead asset
Sparsentan
Phase 3 · Immunoglobulin A Nephropathy

Full Press Release Details

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Patent Application No. 19/253,120, titled “Biphenyl Sulfonamide Compounds for the Treatment of Kidney Diseases or Disorders,” directed to certain methods of using FILSPARI® (sparsentan) in focal segmental glomerulosclerosis (FSGS). Upon issuance, the patent is expected to provide U.S. patent coverage for certain me

Frequently Asked Questions

What is the Notice of Allowance from the USPTO?

It indicates that the USPTO is likely to grant a patent for a specific application.

What does the patent cover?

It covers methods of using FILSPARI (sparsentan) for treating focal segmental glomerulosclerosis.

How does this patent affect Travere Therapeutics?

It strengthens their market position by providing U.S. patent protection for FILSPARI.

What is FILSPARI used for?

FILSPARI is used in the treatment of focal segmental glomerulosclerosis (FSGS).

ShareAdd on Google
Tags: TVTX Viatris Investor Conferences Healthcare Travere Therapeutics FILSPARI sparsentan FSGS U.S. Patent
Last updated: Sep 23, 2026

Biotech snapshot

Cash runway
$489M liquidity · $0M/mo burn
Low dilution risk
Lead asset
SparsentanPhase 3
Immunoglobulin A Nephropathy →

Catalyst track record

+68%
best trade around TVTX's most recent catalyst

Peak hindsight return over a 120-day window, across 10 tracked FDA/PDUFA catalysts for TVTX.

See every catalyst's timing & PoA →